The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma

Completed

• Conditions: Esophageal Squamous Cell Carcinoma
• Interventions: Other: no-Intervention

• Registration Number: NCT06241066
• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Brief Summary

Retrospective analysis of the presence and maturity of tertiary lymphoid structures in pathological sections of patients with esophageal squamous cell carcinoma after surgical treatment. Pay attention to the overall survival and disease free survival of these esophageal squamous cell carcinoma patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01-01
• Primary Completion: 2023-10-31
• Study Completion: 2023-10-31
• Status Verified: 2023-12
• Study First Submitted: 2024-01-25
• Study First Submitted QC: 2024-02-02
• Last Update Submitted: 2024-02-02
• Study First Posted: 2024-02-05
• Last Update Posted: 2024-02-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 359

Inclusion Criteria

• 1. Pathologically diagnosed as esophageal squamous cell carcinoma; 2. Surgery for esophageal cancer; 3. Complete medical records;

Exclusion Criteria

• Patients with a previous history of malignant tumor

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Surgery alone group	no-Intervention	Patients who were diagnosed with esophageal squamous cell carcinoma and underwent esophageal squamous cell carcinoma resection without any prior treatment are included in this group. These patients had not been diagnosed with any other cancer. Finally, 96 patients were included.
Neoadjuvant chemotherapy combined with immunotherapy group	no-Intervention	Patients who were diagnosed with esophageal squamous cell carcinoma and underwent esophageal squamous cell carcinoma resection, and underwent routine chemotherapy combined with immunotherapy before surgery were included in this group. These patients were not diagnosed with any other cancers Finally, 81 patients were included.
Neoadjuvant chemotherapy group	no-Intervention	Patients who were diagnosed with esophageal squamous cell carcinoma and underwent esophageal squamous cell carcinoma resection, and underwent routine chemotherapy before surgery were included in this group. These patients were not diagnosed with any other cancers Finally, 89 patients were included.
Neoadjuvant chemotherapy combined with radiotherapy group	no-Intervention	Patients who were diagnosed with esophageal squamous cell carcinoma and underwent esophageal squamous cell carcinoma resection, and underwent routine chemotherapy combined with radiotherapy before surgery were included in this group. These patients were not diagnosed with any other cancers Finally, 93 patients were included.

Primary Outcome Measures

Name	Time	Method
OS	The time from treatment to death or last follow-up, assessed up to 100 months.	Overall Survival
DFS	The time from treatment to the first recurrence or last follow-up, assessed up to 100 months.	Disease-free Survival

Trial Locations

Locations (1)

Tianjin Cancer Hospital; 🇨🇳 Tianjin, Tianjin, China